TWI343812B - New medicaments for the treatment of chronic obstructive pulmonary disease - Google Patents

New medicaments for the treatment of chronic obstructive pulmonary disease Download PDF

Info

Publication number
TWI343812B
TWI343812B TW092132031A TW92132031A TWI343812B TW I343812 B TWI343812 B TW I343812B TW 092132031 A TW092132031 A TW 092132031A TW 92132031 A TW92132031 A TW 92132031A TW I343812 B TWI343812 B TW I343812B
Authority
TW
Taiwan
Prior art keywords
compound
ethyl
formula
dimethyl
hydroxy
Prior art date
Application number
TW092132031A
Other languages
English (en)
Chinese (zh)
Other versions
TW200423943A (en
Inventor
Bouyssou Thierry
Buettner Frank
Konetzki Ingo
Pestel Sabine
Schnapp Andreas
Schollenberger Hermann
Schromm Kurt
Heine Claudia
Rudolf Klaus
Lustenberger Philipp
Hoenke Christoph
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32185709&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI343812(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of TW200423943A publication Critical patent/TW200423943A/zh
Application granted granted Critical
Publication of TWI343812B publication Critical patent/TWI343812B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW092132031A 2002-11-15 2003-11-14 New medicaments for the treatment of chronic obstructive pulmonary disease TWI343812B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10253282A DE10253282A1 (de) 2002-11-15 2002-11-15 Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung

Publications (2)

Publication Number Publication Date
TW200423943A TW200423943A (en) 2004-11-16
TWI343812B true TWI343812B (en) 2011-06-21

Family

ID=32185709

Family Applications (1)

Application Number Title Priority Date Filing Date
TW092132031A TWI343812B (en) 2002-11-15 2003-11-14 New medicaments for the treatment of chronic obstructive pulmonary disease

Country Status (38)

Country Link
EP (2) EP2025338A1 (cg-RX-API-DMAC7.html)
JP (1) JP4317138B2 (cg-RX-API-DMAC7.html)
KR (1) KR101092247B1 (cg-RX-API-DMAC7.html)
CN (3) CN101735166A (cg-RX-API-DMAC7.html)
AR (2) AR041969A1 (cg-RX-API-DMAC7.html)
AT (1) ATE430569T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003285326B2 (cg-RX-API-DMAC7.html)
BE (1) BE2014C016I2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0316264B8 (cg-RX-API-DMAC7.html)
CA (1) CA2506082C (cg-RX-API-DMAC7.html)
CO (1) CO5570670A2 (cg-RX-API-DMAC7.html)
CY (2) CY1110500T1 (cg-RX-API-DMAC7.html)
DE (2) DE10253282A1 (cg-RX-API-DMAC7.html)
DK (1) DK1562603T3 (cg-RX-API-DMAC7.html)
EA (1) EA008665B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP055774A (cg-RX-API-DMAC7.html)
ES (1) ES2326878T7 (cg-RX-API-DMAC7.html)
FR (1) FR14C0049I2 (cg-RX-API-DMAC7.html)
HR (1) HRP20050432B1 (cg-RX-API-DMAC7.html)
HU (1) HUS1400011I1 (cg-RX-API-DMAC7.html)
IL (1) IL167900A (cg-RX-API-DMAC7.html)
LT (1) LTC1562603I2 (cg-RX-API-DMAC7.html)
LU (1) LU92433I2 (cg-RX-API-DMAC7.html)
ME (1) ME00354B (cg-RX-API-DMAC7.html)
MX (1) MXPA05005081A (cg-RX-API-DMAC7.html)
MY (1) MY136034A (cg-RX-API-DMAC7.html)
NL (1) NL300650I2 (cg-RX-API-DMAC7.html)
NO (2) NO334314B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ540661A (cg-RX-API-DMAC7.html)
PE (1) PE20040694A1 (cg-RX-API-DMAC7.html)
PL (1) PL212238B1 (cg-RX-API-DMAC7.html)
PT (1) PT1562603E (cg-RX-API-DMAC7.html)
RS (1) RS51607B (cg-RX-API-DMAC7.html)
SI (1) SI1562603T1 (cg-RX-API-DMAC7.html)
TW (1) TWI343812B (cg-RX-API-DMAC7.html)
UA (1) UA81276C2 (cg-RX-API-DMAC7.html)
WO (1) WO2004045618A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200502246B (cg-RX-API-DMAC7.html)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
PT1781298E (pt) 2004-04-22 2012-02-03 Boehringer Ingelheim Int Combinações farmacêuticas contendo benzoxazinas para o tratamento de doenças respiratórias
DE102004019539A1 (de) * 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von Atemwegserkrankungen
EP1789394A1 (de) * 2004-05-13 2007-05-30 Boehringer Ingelheim International Gmbh Hydroxy-substituierte benzkondensierte heterozyklen als betaagonisten zur behandlung von atemwegserkrankungen
DE102004024452A1 (de) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolformulierung für die Inhalation von Betaagonisten
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
DE102004024454A1 (de) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102004024451A1 (de) * 2004-05-14 2005-12-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten
DE102004024453A1 (de) * 2004-05-14 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen
US20050256115A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Aerosol formulation for the inhalation of beta-agonists
US7745621B2 (en) 2004-05-14 2010-06-29 Boehringer Ingelheim International Gmbh Long acting bronchodilators for the treatment of respiratory diseases
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
DE102004045648A1 (de) * 2004-09-21 2006-03-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika zur Behandlung von Atemwegserkrankungen
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
DE102005007654A1 (de) 2005-02-19 2006-08-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
DE102005030733A1 (de) * 2005-07-01 2007-01-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen enthaltend langwirksame Beta-2-Agonisten und wenigstens einen weiteren Wirkstoff
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
NZ566068A (en) 2005-08-08 2011-03-31 Argenta Discovery Ltd Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses
AU2006281449B2 (en) * 2005-08-15 2013-01-31 Boehringer Ingelheim International Gmbh Method for producing betamimetics
TWI389692B (zh) * 2005-10-10 2013-03-21 Boehringer Ingelheim Int 用以吸入β-共效劑的氣溶膠調配物
TWI396541B (zh) 2005-10-10 2013-05-21 Boehringer Ingelheim Int 用於治療呼吸疾病之新穎藥物組合
EP1957530A2 (en) 2005-10-21 2008-08-20 Novartis AG Human antibodies against il13 and therapeutic uses
CA2627726A1 (en) * 2005-11-09 2007-05-18 Boehringer Ingelheim International Gmbh Aerosolformulation for inhalation
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
EP1986644A1 (de) * 2006-02-16 2008-11-05 Boehringer Ingelheim International GmbH Arzneimittelkombinationen zur behandlung von atemwegserkrankungen
PE20080142A1 (es) * 2006-03-15 2008-04-14 Boehringer Ingelheim Int Beta-agonistas enantiomericamente puros y sus procedimientos de preparacion
EP2013211B1 (en) 2006-04-21 2012-03-14 Novartis AG Purine derivatives for use as adenosin a2a receptor agonists
EP2057152A1 (de) * 2006-08-07 2009-05-13 Boehringer Ingelheim International GmbH Enantiomerenreine betaagonisten, verfahren zu deren herstellung und deren verwendung als arzneimittel
UY30542A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de agonistas beta
UY30543A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de beta- agonistas
MX2009003185A (es) 2006-09-29 2009-04-03 Novartis Ag Pirazolopirimidinas como inhibidores de lipido cinasa pi3k.
BRPI0718266A2 (pt) 2006-10-30 2014-01-07 Novartis Ag Compostos heterocíclicos como agentes anti-inflamatórios.
CA2673803A1 (en) 2007-01-10 2008-07-17 Irm Llc Compounds and compositions as channel activating protease inhibitors
ATE518847T1 (de) * 2007-01-25 2011-08-15 Boehringer Ingelheim Int Verfahren zur herstellung von betamimetika
ATE499363T1 (de) 2007-05-07 2011-03-15 Novartis Ag Organische verbindungen
NZ585789A (en) 2007-12-10 2012-03-30 Novartis Ag Pyrazine-2-carboxamide derivatives to treat diseases mediated by blockade of the epithelial sodium channel
WO2009087224A1 (en) 2008-01-11 2009-07-16 Novartis Ag Pyrimidines as kinase inhibitors
MX2010013675A (es) 2008-06-10 2011-02-15 Novartis Ag Derivados de pirazina como bloqueadores del canal de sodio epitelial.
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
BRPI0923862A2 (pt) 2008-12-30 2015-07-28 Pulmagen Therapeutics Inflammation Ltd Compostos sulfonamida para o tratamento de distúrbios respiratórios
PL2391366T3 (pl) 2009-01-29 2013-04-30 Novartis Ag Podstawione benzimidazole do leczenia gwiaździaków
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EP2464649A1 (en) 2009-08-12 2012-06-20 Novartis AG Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
ES2709108T3 (es) 2009-08-17 2019-04-15 Intellikine Llc Compuestos heterocíclicos y usos de los mismos
CN102665715A (zh) 2009-10-22 2012-09-12 沃泰克斯药物股份有限公司 治疗囊性纤维化和其他慢性疾病的组合物
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
MX390695B (es) * 2010-09-21 2025-03-21 Intekrin Therapeutics Inc Composiciones farmaceuticas solidas antidiabeticas
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
AU2012220572A1 (en) 2011-02-25 2013-08-29 Irm Llc Compounds and compositions as trk inhibitors
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
WO2013038362A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
JP6165733B2 (ja) 2011-09-16 2017-07-19 ノバルティス アーゲー Ｎ−置換ヘテロシクリルカルボキサミド類
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
ES2558457T3 (es) 2011-09-16 2016-02-04 Novartis Ag Compuestos heterocíclicos para el tratamiento de fibrosis quística
CN104363914A (zh) 2011-11-23 2015-02-18 因特利凯有限责任公司 使用mTOR抑制剂的增强的治疗方案
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
JP2015512425A (ja) 2012-04-03 2015-04-27 ノバルティス アーゲー チロシンキナーゼ阻害剤との組合せ製品及びそれらの使用
WO2014056840A1 (en) 2012-10-09 2014-04-17 Boehringer Ingelheim International Gmbh Beta-2-adrenoceptor agonist for the treatment of cough
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc COMBINING KINASE INHIBITORS AND USES THEREOF
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
KR20160141856A (ko) 2014-04-24 2016-12-09 노파르티스 아게 포스파티딜이노시톨 3-키나제 억제제로서의 피라진 유도체
CA2945212A1 (en) 2014-04-24 2015-10-29 Novartis Ag Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
EP3134396B1 (en) 2014-04-24 2019-09-18 Novartis AG Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
WO2016016822A1 (en) 2014-07-31 2016-02-04 Novartis Ag Combination therapy
EP3551187B1 (en) 2016-12-12 2021-02-17 Boehringer Ingelheim International GmbH Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with olodaterol
HRP20211915T1 (hr) 2016-12-20 2022-03-18 Inke, S.A. Poboljšani postupak dobivanja r-6-hidroksi-8-[1-hidroksi-2-[2-(4-metoksifenil)-1,1-dimetiletilaminoetil]-2h-1,4-benzoksazin-3(4h)-on-hidroklorida
CN109096218B (zh) * 2018-08-06 2020-10-27 上海方予健康医药科技有限公司 盐酸奥达特罗晶型a及其制备方法
CN108997248B (zh) * 2018-08-06 2023-08-01 上海方予健康医药科技有限公司 盐酸奥达特罗晶型b及其制备方法
EP3980121A1 (en) 2019-06-10 2022-04-13 Novartis AG Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis
AU2020338971B2 (en) 2019-08-28 2023-11-23 Novartis Ag Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
CN115768404B (zh) * 2020-06-09 2024-11-08 广州谷森制药有限公司 含乌美溴铵和三苯乙酸维兰特罗的药物制剂
US11331322B1 (en) 2021-09-15 2022-05-17 Santen Pharmaceutical Co., Ltd. Medicament for preventing and/or treating dry eye

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3134590A1 (de) * 1981-09-01 1983-03-10 Boehringer Ingelheim KG, 6507 Ingelheim Neue benzo-heterocyclen
US4460581A (en) * 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
DE3743265A1 (de) * 1987-12-19 1989-06-29 Boehringer Ingelheim Kg Neue ammoniumverbindungen, ihre herstellung und verwendung
EE200200602A (et) * 2000-04-27 2004-04-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pikatoimelised beetamimeetikumid, meetod nende valmistamiseks ja nende kasutamine ravimitena

Also Published As

Publication number Publication date
NO2014005I1 (no) 2014-03-10
ZA200502246B (en) 2006-01-25
ES2326878T3 (es) 2009-10-21
BRPI0316264B8 (pt) 2021-05-25
JP4317138B2 (ja) 2009-08-19
AU2003285326A1 (en) 2004-06-15
CN101735166A (zh) 2010-06-16
BE2014C016I2 (cg-RX-API-DMAC7.html) 2023-03-07
DK1562603T3 (da) 2009-09-07
WO2004045618A2 (de) 2004-06-03
CY2014032I1 (el) 2015-12-09
CN101817800A (zh) 2010-09-01
ECSP055774A (es) 2005-11-22
RS20050361A (sr) 2007-04-10
SI1562603T1 (sl) 2009-10-31
PT1562603E (pt) 2009-06-18
MEP53608A (en) 2011-05-10
WO2004045618A3 (de) 2004-09-30
DE10253282A1 (de) 2004-05-27
NO20052883L (no) 2005-06-14
CA2506082C (en) 2011-06-21
CY1110500T1 (el) 2015-04-29
HRP20050432B1 (en) 2012-01-31
FR14C0049I1 (cg-RX-API-DMAC7.html) 2014-08-08
EA200500715A1 (ru) 2005-12-29
PL375270A1 (en) 2005-11-28
AU2003285326B2 (en) 2009-06-04
IL167900A (en) 2013-06-27
ATE430569T1 (de) 2009-05-15
BR0316264A (pt) 2005-10-11
LU92433I2 (fr) 2014-06-24
CN1713914A (zh) 2005-12-28
ES2326878T7 (es) 2014-03-11
NZ540661A (en) 2007-12-21
LTC1562603I2 (lt) 2016-12-12
MY136034A (en) 2008-07-31
JP2006508140A (ja) 2006-03-09
NL300650I2 (nl) 2017-11-02
CY2014032I2 (el) 2015-12-09
BRPI0316264B1 (pt) 2019-04-09
DE50311502D1 (de) 2009-06-18
AR087241A2 (es) 2014-03-12
CA2506082A1 (en) 2004-06-03
KR20050075013A (ko) 2005-07-19
EP1562603A2 (de) 2005-08-17
EP2025338A1 (de) 2009-02-18
ME00354B (me) 2011-10-10
NO334314B1 (no) 2014-02-03
CO5570670A2 (es) 2005-10-31
EP1562603B1 (de) 2009-05-06
KR101092247B1 (ko) 2011-12-12
RS51607B (sr) 2011-08-31
EA008665B1 (ru) 2007-06-29
PL212238B1 (pl) 2012-08-31
TW200423943A (en) 2004-11-16
HUS1400011I1 (hu) 2022-02-28
MXPA05005081A (es) 2005-07-01
AR041969A1 (es) 2005-06-01
EP1562603B3 (de) 2014-01-08
HRP20050432A2 (en) 2006-06-30
FR14C0049I2 (fr) 2015-07-24
UA81276C2 (en) 2007-12-25
PE20040694A1 (es) 2004-11-23

Similar Documents

Publication Publication Date Title
TWI343812B (en) New medicaments for the treatment of chronic obstructive pulmonary disease
US8044046B2 (en) Medicaments for the treatment of chronic obstructive pulmonary disease
JP4991519B2 (ja) 呼吸器疾患を治療するために持続性ベータ受容体刺激剤模倣薬として使用される新規ベンゾオキサジノン誘導体
JP5044221B2 (ja) 新規な長時間作用性ベータ−２−アゴニスト、及び薬物としての使用
CA2506109A1 (en) Novel dihydroxy-methylphenyl derivatives, method for the production and use thereof as medicaments
CA2501055A1 (en) Novel betamimetics with extended duration of action, method for production and use thereof as medicaments
JP2007533684A (ja) 呼吸道疾患を治療するためのベンゾオキサジン
JPH09507219A (ja) α−２−アドレノセプター作動剤として有用な７−（２−イミダゾリニルアミノ）キノリン化合物
US7244728B2 (en) Long acting betamimetics for the treatment of respiratory diseases
CN101128444A (zh) 用于治疗呼吸系统疾病的新药物
HK1144937A (en) Novel medicaments for the treatment of chronic obstructive pulmonary diseases
TW200404759A (en) New cinnamic acid salts, processes for the preparation thereof and use thereof as medicament
HK1144938A (en) Novel medicaments for the treatment of chronic obstructive pulmonary diseases
MXPA06010577A (en) Benzoxazine for treating respiratory tract diseases